₹555.50
2.78%
Compare
Akums Drugs vs Sun PharmaceuticalAkums Drugs vs Divi's LaboratoriesAkums Drugs vs Piramal PharmaAkums Drugs vs Eris LifesciencesAkums Drugs vs Neuland LaboratoriesAkums Drugs vs NIFTY 50 | MarketN

TL;DR: Financial Overview - Revenue, Profits & Key Metrics

Latest Quarterly: Jun 2025

Income Metrics

Revenue 10.2B
Gross Profit 4.4B 43.17%
Operating Income 920.5M 8.99%
Net Income 646.8M 6.32%
EPS (Diluted) ₹4.15

Balance Sheet Metrics

Total Assets 41.1B
Total Liabilities 10.5B
Shareholders Equity 30.6B
Debt to Equity 0.34

Cash Flow Metrics

Revenue & Profitability Trend

Quarter Income Flow i

Annual Income Flow i

Akums Drugs Income Statement From 2021 to 2025

Metric 2025 2024 2023 2022 2021
Revenue i 40.7B 41.8B 34.7B 36.5B 27.0B
Cost of Goods Sold i 24.7B 25.5B 23.1B 23.8B 17.2B
Gross Profit i 16.1B 16.3B 11.7B 12.7B 9.8B
Gross Margin % i 39.4% 39.0% 33.6% 34.8% 36.3%
Operating Expenses
Research & Development i - - - - -
Selling, General & Administrative i 1.0B 1.1B 1.1B 878.2M 731.4M
Other Operating Expenses i 3.7B 5.0B 3.4B 2.8B 2.1B
Total Operating Expenses i 4.7B 6.1B 4.5B 3.7B 2.8B
Operating Income i 3.1B 3.6B 1.9B 3.2B 2.3B
Operating Margin % i 7.6% 8.5% 5.5% 8.8% 8.5%
Non-Operating Items
Interest Income i 249.9M 120.0M 78.8M 46.3M 61.4M
Interest Expense i 304.1M 506.1M 459.7M 163.4M 63.9M
Other Non-Operating Income - - - - -
Pre-tax Income i 3.5B -452.8M 1.5B -1.9B 1.7B
Income Tax i 14.8M -460.7M 524.8M 576.8M 488.3M
Effective Tax Rate % i 0.4% 0.0% 34.9% 0.0% 28.3%
Net Income i 3.4B 7.9M 978.2M -2.5B 1.2B
Net Margin % i 8.4% 0.0% 2.8% -6.9% 4.6%
Key Metrics
EBITDA i 5.1B 5.1B 3.4B 4.2B 3.1B
EPS (Basic) i ₹22.60 ₹0.05 ₹6.21 ₹-15.94 ₹7.80
EPS (Diluted) i ₹22.60 ₹0.05 ₹6.21 ₹-15.94 ₹7.80
Basic Shares Outstanding i 149609486 157393996 157393996 157393996 157393996
Diluted Shares Outstanding i 149609486 157393996 157393996 157393996 157393996

Income Statement Trend

Join Our India Telegram Channel

Get Instant Market Updates: 52-Week High/Low Alerts, Breakout Notifications & Expert Stock Analysis Delivered To Your Phone. Join Traders Making Informed Decisions Daily!

Join Now →

Akums Drugs Balance Sheet From 2021 to 2025

Metric 2025 2024 2023 2022 2021
Assets
Current Assets
Cash & Equivalents i 1.0B 1.1B 516.1M 551.4M 220.7M
Short-term Investments i 4.8B 1.8B 988.9M 481.6M 653.2M
Accounts Receivable i 7.7B 8.3B 8.5B 8.8B 5.3B
Inventory i 6.8B 6.3B 7.3B 7.2B 4.3B
Other Current Assets 22.4M 66.1M 51.0M 11.0M 33.1M
Total Current Assets i 22.7B 19.4B 19.2B 18.9B 11.6B
Non-Current Assets
Property, Plant & Equipment i 2.3B 3.2B 3.2B 2.5B 2.1B
Goodwill i 124.3M 110.1M 100.3M 97.7M 354.2M
Intangible Assets i 83.0M 68.8M 59.0M 56.4M 53.4M
Long-term Investments - - - - -
Other Non-Current Assets 246.0M - - - -
Total Non-Current Assets i 18.4B 15.8B 13.4B 11.8B 10.1B
Total Assets i 41.1B 35.2B 32.7B 30.7B 21.7B
Liabilities
Current Liabilities
Accounts Payable i 6.4B 5.3B 5.7B 5.9B 3.4B
Short-term Debt i 208.8M 4.2B 4.3B 3.5B 1.0B
Current Portion of Long-term Debt - - - - -
Other Current Liabilities 391.4M 1.0M 225.1M - 8.7M
Total Current Liabilities i 8.9B 12.1B 12.7B 12.7B 5.8B
Non-Current Liabilities
Long-term Debt i 673.3M 1.5B 1.9B 437.4M 290.3M
Deferred Tax Liabilities i 186.2M 121.5M 253.0M 393.0M 412.7M
Other Non-Current Liabilities 205.6M 174.3M 128.9M 15.7M 12.6M
Total Non-Current Liabilities i 1.6B 15.9B 12.8B 11.7B 7.0B
Total Liabilities i 10.5B 28.0B 25.4B 24.4B 12.8B
Equity
Common Stock i 306.2M 286.1M 286.1M 143.1M 13.0M
Retained Earnings i 18.3B 6.3B 6.4B 5.6B 8.3B
Treasury Stock i - - - - -
Other Equity - - - - -
Total Shareholders Equity i 30.6B 7.2B 7.2B 6.3B 8.9B
Key Metrics
Total Debt i 882.1M 5.7B 6.2B 3.9B 1.3B
Working Capital i 13.8B 7.3B 6.6B 6.2B 5.8B

Balance Sheet Composition

Akums Drugs Cash Flow Statement From 2021 to 2025

Metric 2025 2024 2023 2022 2021
Operating Activities
Net Income i 3.5B -452.8M 1.5B -1.9B 1.7B
Depreciation & Amortization i - - - - -
Stock-Based Compensation i - - - - -
Working Capital Changes i -898.8M 686.5M -254.0M -6.1B -554.4M
Operating Cash Flow i 2.6B 564.4M 1.4B -7.9B 1.1B
Investing Activities
Capital Expenditures i -2.6B -2.9B -2.9B -2.6B -818.7M
Acquisitions i - 0 -15.8M -106.6M -599.8M
Investment Purchases i -3.1B -634.8M -449.9M - -
Investment Sales i - 0 0 243.6M -
Investing Cash Flow i -5.7B -3.5B -3.1B -2.4B -1.4B
Financing Activities
Share Repurchases i - - - - -
Dividends Paid i - - - - -
Debt Issuance i 0 102.9M 1.4B 200.2M 11.6M
Debt Repayment i -1.2B -358.6M -107.6M -111.2M -350.2M
Financing Cash Flow i 1.6B -491.9M 1.8B 2.6B -735.2M
Free Cash Flow i 1.9B 1.9B -1.5B -2.3B 478.0M
Net Change in Cash i -1.5B -3.4B 66.2M -7.7B -1.0B

Cash Flow Trend

Akums Drugs Key Financial Ratios

Valuation Ratios

P/E Ratio (TTM) 25.39
Forward P/E 21.47
Price to Book 2.58
Price to Sales 1.91
PEG Ratio 15.45

Profitability Ratios

Profit Margin 7.47%
Operating Margin 9.25%
Return on Equity 11.04%
Return on Assets 8.22%

Financial Health

Current Ratio 3.95
Debt to Equity 2.85

Per Share Data

EPS (TTM) ₹20.89
Book Value per Share ₹205.37
Revenue per Share ₹278.15

Peer Financial Comparison

Company Market Cap P/E Ratio P/B Ratio ROE Profit Margin Debt/Equity
AKUMS 82.6B 25.39 2.58 11.04% 7.47% 2.85
Sun Pharmaceutical 3.9T 36.73 5.15 15.08% 19.21% 6.68
Divi's Laboratories 1.7T 67.11 10.82 14.64% 24.04% 0.58
Piramal Pharma 199.7B 269.79 2.47 1.12% -1.84% 60.08
Eris Lifesciences 193.4B 44.25 6.15 10.75% 14.06% 68.19
Neuland Laboratories 184.8B 103.42 11.41 17.06% 2.29% 16.33
Nippun Rana

Nippun Rana

Chasing the market trend!

Hi, I’m Nippun, a tech enthusiast from Haryana, India. I have been coding since 2010 and using my coding skills in the share market since 2020. I have been coding scripts in Pinescript that work on Tradingview app/web. I love learning about new technology and applying it to solve real-world problems. Coding and share-market are my passions, and I enjoy finding and fixing bugs in code. I aim to share my skill set and experience that can positively impact society. Feel free to connect with me, an...

Financial data is updated regularly. All figures are in the company's reporting currency.